A novel technique for the production of hybrid antibodies.
Chemically linked bifunctional antibodies (heteroconjugates) composed of one antibody specific for the TcR/CD3 complex on cytotoxic T cells and another specific for viral antigens expressed on the surface of infected cells have been shown to redirect CTL to lyse virus-infected cells. Hybrid antibodies are bifunctional antibodies produced by the fusion of two hybridomas. As a result of their native dimeric immunoglobulin structure, hybrid antibodies may be more effective than heteroconjugates in vivo. We have developed a unique method for production of hybrid antibodies by infecting each hybridoma with a different retrovirus vector which confers resistance to either G418 or methotrexate. The hybridomas are fused and selected in medium containing both inhibitors. Using this technique, we have produced hybrid antibodies made up of one antibody combining site which binds to the TcR and a second specific for the hemagglutinin of X-31 influenza virus. We show that this hybrid antibody effectively mediates the lysis of virus-infected cells in the presence of appropriate CTL. Thus hybrid antibodies as well as heteroconjugates can redirect CTL to lyse virus-infected targets.